Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11231
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrossmann, Mathisen
dc.contributor.authorHamilton, Emma Jen
dc.contributor.authorGilfillan, Christopheren
dc.contributor.authorBolton, Damien Men
dc.contributor.authorJoon, Daryl Limen
dc.contributor.authorZajac, Jeffrey Den
dc.date.accessioned2015-05-16T00:49:11Z
dc.date.available2015-05-16T00:49:11Z
dc.date.issued2011-03-21en
dc.identifier.citationMedical Journal of Australia; 194(6): 301-6en
dc.identifier.govdoc21426285en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11231en
dc.description.abstractAndrogen deprivation therapy (ADT) in men with prostate cancer increases the risk of osteoporotic fractures, type 2 diabetes and, possibly, cardiovascular events. There is considerable uncertainty about the risk-benefit ratio of ADT in non-palliative treatment; the benefits of ADT in treating non-metastatic prostate cancer need to be carefully weighed against the risks of ADT-induced adverse events. Baseline assessment of bone health at the initiation of ADT should include measurement of bone mineral density (BMD) by dual energy x-ray absorptiometry and, in men with osteopaenia, a thoracolumbar spine x-ray. General measures to prevent bone loss, including regular physical activity, as well as ensuring calcium and vitamin D sufficiency, should be instituted routinely. All men with a previous minimal trauma fracture should receive pharmacological therapy unless contraindicated; for those who have not sustained a minimal trauma fracture, treatment is advised if the BMD T score is ≤ - 2.0, or if the 10-year risk of a major osteoporotic fracture exceeds 20%. Men with prostate cancer who are receiving ADT should be closely monitored for weight gain and diabetes; intensive lifestyle intervention is recommended to prevent ADT-induced weight gain and insulin resistance. Management of the metabolic sequelae of ADT includes optimal reduction of cardiovascular risk factors, with particular attention to weight, blood pressure, lipid profile, smoking cessation, and glycaemic control.en
dc.language.isoenen
dc.subject.otherAbsorptiometry, Photonen
dc.subject.otherAgeden
dc.subject.otherAndrogen Antagonists.adverse effects.therapeutic useen
dc.subject.otherAntineoplastic Agents, Hormonal.adverse effects.therapeutic useen
dc.subject.otherBone Density.drug effectsen
dc.subject.otherCombined Modality Therapyen
dc.subject.otherDiphosphonates.therapeutic useen
dc.subject.otherExercise.physiologyen
dc.subject.otherHumansen
dc.subject.otherLife Styleen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherOsteoporosis.chemically induced.diagnosis.therapyen
dc.subject.otherOsteoporotic Fractures.diagnosis.epidemiologyen
dc.subject.otherPractice Guidelines as Topicen
dc.subject.otherPrognosisen
dc.subject.otherProstatic Neoplasms.drug therapy.pathologyen
dc.subject.otherRisk Assessmenten
dc.subject.otherTreatment Outcomeen
dc.titleBone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.en
dc.typeJournal Articleen
dc.identifier.journaltitleMedical Journal of Australiaen
dc.identifier.affiliationAustin Health/Northern Health, University of Melbourne, Melbourne, Victoria, Australiaen
dc.description.pages301-6en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/21426285en
dc.type.austinJournal Articleen
local.name.researcherBolton, Damien M
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptEndocrinology-
crisitem.author.deptUrology-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

40
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.